Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
A new study found that circulating tumor DNA can identify stage II colon cancer patients who benefit from chemotherapy, sparing others the need for treatment. The study showed reduced use of chemotherapy without compromising survival rates.
Researchers analyzed 2,049 breast cancer samples to compare genomic alterations across younger and older age groups. Younger patients had higher rates of BRCA1 mutations and lower rates of CDH1 and PIK3CA mutations.
A phase 2 trial of the experimental drug adagrasib showed a 42.9% objective response rate and median overall survival of 12.6 months in patients with KRAS-mutated non-small cell lung cancer. The treatment also achieved a 33.3% response rate in patients with stable brain metastases.
Researchers found that combining chemotherapy with immunotherapy increased one-year survival rates for patients with advanced pancreatic cancer, with anti-PD-1/chemo regimen showing the highest response. The study identified key immune system biomarkers associated with better outcomes, offering new hope for precision oncology.
Researchers at Karolinska Institutet have successfully repurposed a cancer drug to target neuroinflammatory diseases like multiple sclerosis. A novel drug carrier was developed to deliver the treatment specifically to microglia, reducing inflammation and disease progression.
A combination of ramucirumab and pembrolizumab reduced the risk of death by 31% compared to standard care in advanced non-small cell lung cancer patients who had previously failed immunotherapy. The study found that these patients lived significantly longer, with a mean overall survival time of 14.6 months.
A new cell therapy has been developed to target and eliminate leukemia stem cells that cause disease relapse. The treatment uses genetically engineered T cells with a chimeric antigen receptor that recognizes specific markers on these cancer cells.
Researchers at the University of Chicago's Pritzker School of Molecular Engineering have developed a version of interleukin-12 that is activated only when it reaches a tumor, reducing side effects. The new 'masked' molecule has shown promising results in eliminating cancer cells and outperforming existing immune therapies.
Researchers at Washington University School of Medicine have developed an investigational drug that targets synovial sarcoma, a rare and aggressive type of cancer. The drug, ACXT-3102, works by interfering with the metabolic pathway of the tumor cells, causing them to die from the buildup of reactive oxygen species.
New research suggests vitamin D can effectively prevent ovarian cancer by restoring the body's natural defenses. The study found that vitamin D counteracts the process of peritoneal metastasis, which allows cancer cells to spread, and strengthens the barrier effect of mesothelial cells.
Pharmaceutical scientist Hans Lennernäs will collaborate with JGU's Peter Langguth to investigate ways to mitigate chemotherapy side effects. The goal is to identify active substances that can counteract adverse reactions and develop effective drugs.
Despite the US leading in cancer care spending, it doesn't show substantial lower cancer mortality rates compared to other high-income countries. Cancer care spending across 22 high-income countries reveals a lack of correlation with cancer-related mortality rates.
Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.
Researchers have found that mutational signatures, which reflect a collection of mutations across the genome, can accurately predict drug response in cancer cells. The study suggests that these signatures may hold the key to better cancer therapies and could be used to predict treatment response.
Recent studies from Cedars-Sinai have shed light on the importance of a gene in embryo development and its potential link to physical abnormalities. Additionally, research has shown that getting vaccinated against Covid-19 can strengthen immune responses in patients with inflammatory bowel disease. The institution is also working on ne...
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.
A team of researchers at NYU Abu Dhabi has discovered a novel structural modification in AMP-activated protein kinase that could pave the way for more effective cancer treatments. The study found that a specific enzyme cleaves and traps the protein in the cell nucleus, rendering it resistant to chemotherapy and radiotherapy.
Research found that men taking abiraterone or enzalutamide plus hormone therapy had a higher risk of metabolic and cardiovascular issues than those undergoing hormone therapy alone. This increased risk was observed in patients with Medicare health insurance, who were significantly older than those in clinical trials.
A study by Weill Cornell Medicine investigators has revealed the cause and potential precision therapies for a type of aggressive blood cancer called diffuse large B cell lymphoma (DLBCL). The research found that SETD2 gene mutations can lead to an accumulation of DNA damage, causing cancer cells to grow uncontrollably.
A landmark trial found that a widely used diabetes drug, metformin, is not effective against the most common forms of early-stage breast cancer. However, researchers discovered a potential benefit for individuals with HER2-positive breast cancer, which accounts for about 20% of all breast cancers.
Researchers at University of Utah Health have found a natural chemical in soft corals that shows promise in treating cancer. The discovery allows for the first steps of re-creating the chemical in the laboratory, opening up possibilities for producing it on a large scale.
A research team led by Professor Youdong Mao has developed a new method using time-resolved cryo-electron microscopy and machine learning-based 4D reconstruction to visualize the USP14-proteasome system in atomic detail. This reveals a 'multiverse' of parallel reality pathways, allowing for targeted inhibition of cancer cells.
Researchers developed CancerOmicsNet, a graph neural network model that integrates multiple heterogeneous data to predict cancer cell growth rate after drug treatment. The model achieved significantly higher cross-validated accuracy than other approaches on the same data.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
A minimally invasive device combined with molecular biomarkers has shown a 90% success rate in detecting esophageal squamous cell carcinoma, the predominant subtype of esophageal cancer. Early detection is crucial to improve survival rates, as symptoms often become apparent too late for effective treatment.
A multidisciplinary research group uses magnetotactic bacteria to create nanomagnetic structures, which can be steered through the human body via external magnetic fields. They have developed a new method to measure the magnetic properties of individual nanomagnets in biological entities, enabling precise control over these structures.
A recent study found that 70% of adults with stage 3 or 4 cancer were at risk of drug-drug interactions, highlighting the importance of deprescribing medications to avoid harm. The study's results emphasize the need for education and problem-solving to address polypharmacy in older adults with cancer.
New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...
A new lymphoma treatment, zanubrutinib, has been found to be effective in 80% of patients with marginal zone lymphoma, resulting in significant cancer shrinkage. However, its impact on follicular lymphoma is less pronounced.
Researchers developed an algorithm to quickly identify two cancer drugs that work well together, reducing testing time from three years to eight weeks. The new method uses gene expression data to prioritize potential combinations and has been confirmed in lab tests.
Researchers at Massachusetts General Hospital have developed a series of animal models to test nonsurgical drug treatments for congenital giant nevi, which can cause large and permanent scars. The studies found that some treatments led to significant nevus regressions and even prevented skin cancer formation.
Researchers found that targeting both tumor and lymph node microenvironments with nanomedicine improves treatment response for metastatic triple negative breast cancer. Long-term tumor remission was achieved in mice models using nanoparticles to deliver immune-modulating drugs.
A UC Davis study found a critical agent keeping KSHV dormant and undetected by the immune system. The virus is linked to various cancers and AIDS-related diseases. The researchers identified CHD4 as a key regulator of the latency-lytic switch, allowing the virus to stay silent.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
Researchers identified a relationship between genetic mutations that promote cancer growth and those that help cells evade the immune system. This finding has implications for developing more effective immunotherapies by understanding how cancer cells balance growth and invisibility.
Researchers at Weill Cornell Medicine found that tumors recruit nearby cells called fibroblasts to work as their enablers by releasing lactate. This finding suggests that future drug treatments could target this defense mechanism to help cancer patients.
Researchers found phosphatidylinositol bisphosphate (PIP2) essential for epithelial cell-cell adhesion and maintaining cellular identity. PIP2 regulates epithelial properties by recruiting Par3 to the plasma membrane, facilitating the formation of adherens junctions and preventing epithelial-mesenchymal transformation.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Cancer incidence is projected to double in SSA by 2040, with 1.4 million cases per year expected without rapid interventions. Women are more affected by cancer than men in the region, with breast and cervical cancers among the most common types.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
A recent study by Weill Cornell Medicine and Dana Farber Cancer Institute reveals that CDC7 is replaceable by CDK1 in cell division, opening up new avenues for cancer therapies. The finding highlights the complex molecular orchestration of the cell cycle and suggests a powerful new strategy against cancer.
The S1216 study showed an unprecedented median OS of 70 months in the control arm, outperforming previous results by 24 months. This extended survival was attributed to additional life-prolonging treatments patients received after completing the trial therapy.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
A new study from Montefiore Einstein Cancer Center found that CAR-T therapy was effective in Black and Hispanic patients, with outcomes comparable to those of white and Asian patients. The study showed no statistical differences in clinical outcomes or side effects among racial and ethnic backgrounds.
The composition of microorganisms living in the gut influences response to conventional cancer treatments and novel immunotherapies. Recent studies suggest that targeting the gut microbiome could diminish side effects of chemotherapy, while diet, probiotics, and antibiotic medications may also impact clinical responses.
Cancer cells employ a unique defense mechanism to evade the effects of radiation treatment by exploiting an enzyme called Caspase-activated DNase (CAD). Removing CAD from cancer cells increases the effectiveness of radiotherapy. Researchers hope their discovery can lead to the development of targeted drugs to enhance cancer treatment.
Researchers from Columbia University have developed a plug-and-play multi-organ chip, customized to the patient, consisting of engineered human heart, bone, liver, and skin linked by vascular flow. The model allows for long-term studies and can be optimized for personalized therapy optimization in cancer and systemic diseases.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Texas A&M University developed a low-cost, minimally invasive wireless device that uses photodynamic therapy to kill cancer cells. The device enables precise and safe treatment options during surgery, potentially reducing the need for additional treatments like chemotherapy.
Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.
Deleting or inhibiting a protein called lysine-specific demethylase 1 (LSD1) may curb the growth of oral squamous cell carcinoma tumors. The study found that disrupting LSD1 promotes anti-tumor immunity, which can help fight cancer. The discovery could lead to new and potentially more effective therapies for oral cancer patients.
A study by Brigham and Women's Hospital found that more than half of cancer centers do not publicly disclose payer-specific prices for patients with private health insurance. The study also revealed significant markups in drug prices, ranging from 120% to 630% above the hospital cost.
Research from Weill Cornell Medicine found that less prostate cancer screening has reduced overdiagnosis, but increased incidence of high-grade and metastatic disease. The study analyzed over 438,000 men with newly diagnosed prostate cancer between 2010 and 2018.
A study published in Cancer Medicine suggests that exosomes produced by adipose-derived mesenchymal stem cells can effectively deliver RNA-based anti-cancer treatments to bladder cancer tumors. This novel approach shows promise as a potential therapeutic agent for bladder cancer treatment, offering new hope for patients.
The ESMO Breast Cancer Congress 2022 event will present more than 200 studies on various aspects of breast cancer, including new treatments and innovative clinical practices. The congress will be held onsite in Berlin, Germany, and online, offering a platform for breast cancer specialists to share knowledge and improve patient outcomes.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
Researchers at Aarhus University have developed improved DNA nanostructures that can assemble biomolecules with multiple functions, increasing the effectiveness of cancer treatment. The new structures are more stable, non-toxic, and immune system-friendly than previous versions.